Saudi study reports 27% of those injected with experimental mRNA C19 “vaccines” suffered cardiac issues

From here:

20240210-27678-1rqn0hz.pdf (cureus.com)

Sheriff M M, Marghalani R A, Almana O M, et al. (January 11, 2024) A Study on the Self-Reported Physician-Diagnosed Cardiac Complications Post mRNA Vaccination in Saudi Arabia. Cureus 16(1): e52108. DOI 10.7759/cureus.52108

“Results

Significant associations were found among demographic variables, vaccination behaviors, health diagnoses, and perceptions of self-reported physician-diagnosed cardiac complications post mRNA vaccination in Saudi Arabia.

Key findings included a high mRNA vaccine uptake with a frequency of 747 (92.79%) and a mere frequency of 218 (27.11%) reporting cardiac complications post vaccination. The study highlighted diverse influences on vaccine decisions, with a frequency of 384 (47.76%) expressing neutral confidence in vaccine safety.

The study contributes to the global understanding of mRNA vaccine safety, emphasizing the unique Saudi demographic context. Methodological rigor, ethical considerations, and acknowledgment of  limitations enhance credibility. Collaborative efforts and tailored recommendations for public health policies and communication strategies are underscored.”

“Sample size

The study's sample size was determined using the Raosoft online sample calculator (Raosoft Inc., Seattle, WA), targeting a 95% confidence level with a margin of error within ±5%.

The decision to select a sample size of 804 participants for the cross-sectional study on self-reported physician-diagnosed cardiac complications post mRNA vaccination in Saudi Arabia was influenced by several crucial factors, including the anticipated variability in the population regarding cardiac complications, the desired confidence level and margin of error for accurate estimates, and the statistical power needed to detect significant effects.

Additionally, the study's design, the complexity of the variables involved, and the planned analyses played a role in determining the optimal sample size. Practical considerations, including available resources and potential constraints, have also influenced this decision.

The chosen sample size reflected a careful balance between statistical precision and feasibility, aiming to provide meaningful insights into the incidence and nature of cardiac complications in the specific demographic context of Saudi Arabia.

The confidence level represents the certainty with which conclusions about the population are based on the sample, as the common choices are 95% or 99%. A higher confidence level provided a larger sample size. The calculated sample size required was 804, based on inclusion criteria set by a specialist critical care professional [25].”

Childre’s Health Defence covered the study here:

27% of Saudis in 'Bombshell' Study Experienced Heart Issues After mRNA COVID Shots • Children's Health Defense (childrenshealthdefense.org)

“The onset of cardiac complications varied among participants, with 14.55% experiencing symptoms within one month of vaccination and others reporting issues up to 12 months or longer.”

“TrialSite News reported on the “bombshell Saudi Arabian study” on Wednesday.  Founder, Daniel O’Connor, told The Defender that while the study has limitations and was designed to look for cardiac complications, “The rate of hospitalized cases was certainly notable, especially given the existing cardiac (myocarditis/pericarditis) signal associated with the vaccines.”

Cardiologist and epidemiologist Dr. Peter A. McCullough said that in addition to the large number of cardiovascular symptoms warranting hospitalization, 15.8% landed in an intensive care unit (ICU).”

You can check out the tendencies and limitations of a meta-analysis of 24,000 clinical trials here:

(100) Yet Another Excellent Explainer About P-Values in Randomized Trials (substack.com)

Onwards!!

Please subscribe ten dollars a month or annually for 100 bucks. You can also donate via Ko-fi – any amount from three dollars upwards. Ko-fi donations here: https://ko-fi.com/peterhalligan